Product Name: MST1 (179-187) pT183
Product Number: PE-04AQW95
Size: 200 µg      Price:43.00
1 mg      $US85.00
5 mg      201.00
Peptide Name: MST1 (179-187) pT183

Product Use: Services as a blocking peptide for use with the MST1-pT183 rabbit polyclonal antibody (Cat. No.: AB-PK871) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. T183 stimulates phosphotransferase activity. Phosphorylation induces protein ubquitination and degradation, and regulates molecular association.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: AKRN-pT-VIGT

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1212.29 Da

Peptide Purity Percent after Synthesis and Purification: >90

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: MST1 - pT183 phosphosite-specific antibody (Cat. No.: AB-PK871)

Scientific Background: MST1 (STK4) is a protein-serine/threonine kinase of the STE group and STE20 family. It can induce apoptosis following stress activation. MST1 activity can occur in the nucleus and can be via condensation of chromatin and fragmentation of intranucleosomal DNA. It is activated by caspase-cleavage. Full activation requires homodimerization and autophosphorylation of T183; MST1 phosphotransferase activity can be lost with a T183A mutation. Proteolytic cleavage of MST1 during apoptosis can be reduced with the D326N and D349N mutations. Homodimerization and autophosphorylation are lost with a L444P mutation. It leads to the inactivation of the YAP1 oncoprotein by activating downstream kinases such as LATS1 and LATS2, which phosphorylate YAP1 to prevent it from translocating to the nucleus and transcribing cell proliferation and migration genes. MST1 can also promote apoptosis by preventing the deacetylation of p53/TP53, thus promoting p53-dependent transcription and apoptosis. It is also able to inhibit the PKB/Akt1 pathway. MST1 is linked to pancreatic cancer, which is a rare cancer that does not have characteristic symptoms but is related to the integrated breast cancer and pancreatic cancer pathways.